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I. INTRODUCTION 
In discussing the two-signal concept of selflnonself discrimination. Melvin Cohn 
extolled the virtues of immunological hypotheses that accommodate all relevant 
observations and therefore enunciate principles. as opposed to concise "small theo-
ries" that explain only a few facts [I]. Cohn's points are exemplified by transplanta-
tion. which developed throughout much of its modern history in the absence of a 
unifying general principle. The inability to evolve an encompassing explanation for 
observations made in human and animal allograft recipients. or in surrogate in 
vitro models. drove much of transplantation research down the same reductionist 
pathway as that of its handmaiden. immunology. 
The resulting triumph of detail over concept can be traced to two premises 
that were introduced into the still fragile base of transplantation immunology be-
tween 1944 and 1959. The first was that the events following transplantation could 
be defined in terms of one-way immune reactions: host versus graft (HVG) and 
graft versus host (GVH). This was a potentially defensible framework from which 
important experiments could be formulated. However. when the first premise was 
combined with a second assumption. namely. that whole organ allograft "accep-
tance" must be by different mechanisms than the chimerism-dependent acquired 
tolerance. by Billingham. Brent. and Medawar [2.31. the result was derivative 
dogma that we have called "the one-way paradigm" (4). 
11. THE Y IN THE ROAD: 1962 
Ironically. the first examples of successful human renal transplantation were di-
rectly responsible for establishment of t he intellectually disorienting one-way para-
digm. Until 1959. the production of chimerism by donor leukocyte infusion in 
preparation for organ allotransplantation had been a much anticipated natural 
extension [5,6) of the neonatal tolerance models [2.3) and the adult rodent ana-
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logues in which recipient conditioning by cytoablation was required for donor celI 
engraftment [7,8]. The threat of graft-versus-host disease (GVHD) [9,10] restricted 
this strategy to closely histocompatible donor/recipient pairs [5,6,8-11]. However, 
when long survival of functioning human kidney alIografts was accomplished in 
sublethally irradiated recipients (1959-62) without donor leukocyte infusion [12-14] 
and then regularly (from 1962 onward) with the additional omission of cytoreduc-
tion under continuous pharmacological immunosuppression [l 5-18], both chime-
rism and the need for recipient cytoablation seemingly had been eliminated as condi-
tions for organ allograft acceptance. 
Once this thought was embedded into the catechism of organ transplantation, 
it was not challenged for the next 30 years. The first casualty of the consensus was a 
hypothesis by Simonsen [19] and Michie, Woodruff. and Zeiss [20]. who postulated 
(in 1960-61) that the two populations of immune cells in neonatally tolerant mice 
managed to coexist in a stable state by becoming mutually nonreactive while retain-
ing the ability to function collaboratively (Le., in a joint immune response to infec-
tion). This heretical suggestion presaged the active network hypotheses of tolerance 
of Jerne [21], Coutinho [22], and Cohen [23]. 
The Simonsen hypothesis was recanted in 1962 [241, ostensibly because no 
experimental support could be found for it. More importantly, however, the hy-
pothesis had been advanced in a nonreceptive climate wherein nothing less than 
clonal deletion was being seriously considered as the explanation for acquired trans-
plantation tolerance. The disputes during the immediately preceding years about 
clonal selection as the basis for selflnonself delineation seemingly had achieved 
closure with the ultimate imprimatur of the Nobel Prize, which was awarded to 
MacFarland Burnet in 1960 [25,26]. 
It was no coincidence that the 1960 colaureate with Burnet was Peter Brian 
Medawar, whose observations in the neonatal tolerance model (with Rupert Billing-
ham and Leslie Brent [2,3,11]) were widely considered to be a validation of Burnet's 
prediction that developing lymphocytes with an open repertoire of receptors could 
be purged of self-reactive cells before they achieved functional maturity. Similar 
tolerance produced in radiation chimeras [7,8] also was viewed as an iatrogenically 
engineered simulation of ontogeny. However, the argument for clonal deletion as 
the key mechanism of either variety of acquired tolerance was not beyond criticism, 
as has been pointed out by Schaffner [25,26], Cohn [II, Nossal [27], and Tauber 
[28]. 
All factors considered, it was difficult to envision transplantation as a biologi-
cally sound undertaking and. in fact. Burnet did not. In 1961, we wrote in the New 
England Journal of Medicine that "much thought has been given to ways by which 
tissues or organs not genetically and antigenically identical with the patient might be 
made to survive and function in the alien environment. On the whole the present 
outlook is highly unfavorable to success." [29]. 
III. THE ONE-WA Y PARADIGM 
A. Organ Transplantation . 
Part 01 the appeal of the simplistic one-way paradigm that emerged from the 1959-
63 period was the compatibility of this conceptual framework with Medawar's defi-
nition ot rejection as a unidirectIOnal host versus defenseless graft (HVG) immune 
i 
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response [30] (Figure I A). When the one-way in vitro tests of immune reactivity 
were developed [31.32], they were automatically accepted as "minitransplant mod-
els," the results from which were assumed to be directly applicable to in vivo circum-
stances. 
B. Bone Marrow Transplantation 
From the perspective of the early 1960s, it also seemed logical to interpret the 
tolerance induced in rodents with splenocyte (2.3] or subsequently bone marrow 
transplantation (3,7,8,11) as transposed examples of the one-way paradigm (Figure 
1B) in which the GVH reaction mounted by the immunologically competent allo-
graft rejected the defenseless recipient unless there was a high degree of histocom-
patibility. This frame of reference guided the major histocompatibility complex-
(MHC)-limited strategies of recipientcytoablation and "replacement" [7,8] that 
eventually led to successful clinical bone marrow transplantation in humans - first 
by Mathe et a1. [33] and with mounting frequency after 1968 [34-37]. The clinical 
achievements encouraged the belief that cytoablation (or cytoreduction) to "make 
microenvironmental space" was a necessary condition for donor leukocyte engraft-
ment (reviewed in Ref. 38). in spite of early [39.40] and recent evidence (41) to the 
contrary. 
Thus. as had occurred earlier with the engraftment of human kidneys, the 
success of clinical bone marrow transplantation strengthened the grip of the one-
way paradigm. notwithstanding its inability to explain why organ transplantation 
was governed by different rules than those for bone marrow transplantation (Table 
I). At the root of the dilemma lay the assumption that chimerism. the sine qua non 
of bone marrow transplantation. was irrelevant to an explanation of successful 
organ transplantation. 
IV. THE TWO·WAY PARADIGM 
A. Human Observations 
A connection between the chimerism of hematolymphopoietic transplantation and 
the successful engraftment of whole organs was made with the discovery in 1992 of 
persistent donor leukocytes (microchimerism) up to 30 years postoperatively in the 
peripheral tissues or blood of human kidney. liver. and other organ recipients [42-
46] (Figure I C). The donor cells were few in number. requiring sensitive immunocy-
tochemical and polymerase chain reaction (peR) techniques for detection. Never-
theless. we were able to postulate that the donor-derived leukocytes constituted 
one limb of antagonistic but ultimately reciprocally attenuated or abrogated HVG 
(rejection) and GVH reactions [42-471· 
In this context. disruption of the leukocyte interaction by the host cytoablation 
used to prepare bone marrow recipients. but not the recipients of whole organs. was 
responsible for the disparities in the two different kinds of transplantation (Table 
1). The cancelling effect of the (WO immunoeyte populations under the conditions 
of postoperative immunosuppression used for organ transplantation explained the 
poor prognostic discrimination 01 human leukocyte antigen tHLA) matching as well 
JS the raritv of GVHD alter the enl!rattment 01 immunologicallv active organs such 
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Transplantation Tolerance 
Table 1 Differences Between Conventional Bone Marrow and Organ 
Transplantation 
Bone marrow Organ 
Yes <- Recipient cytoablation' No 
Critical MHC compatibility Not critical 
GVHD Principal complication Rejection 
Common <- Drug-free state Rare 
Tolerance Term for success .. Acceptance'" 
'All differences derive from this therapeutic step. which in effect establishes an unopposed 
GVH reaction in the bone marrow recipient. whose countervailing immune reaction is 
eliminated. MHC. major histocompatibility complex; GVHD. graft-versus-host disease. 
hOr "operalionaltolerance." 
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as the intestine and liver. It was obvious that the characteristic cycle of crisis and 
resolution. first observed in drug-immunosuppressed kidney recipients and most 
practically monitored by serial changes in allograft function [16], was the product 
of a dual immune reaction (Figure 2). At the same time as the peripheral migration 
of the donor cells. there was an influx of recipient cells that did not cause graft 
damage when adequate immunosuppression was given (Figure IC) [44,45,48-521. If 
transplantation was successful. both the allograft and the recipient became genetic 
composites. 
It also was proposed that bone marrow and organ transplantation were. in 
fact. mirror images. resulting from the drastically different treatment strategies 
[4,421. This contention has been supported by reports describing a trace residual 
population of recipient leuKocytes in essentially all human bone marrow recipients. 
Immune 
reaction "-.-. ------GVH ------::K~ .. K;K":_~:;: • K-K-K"::::"D-D-D;;::D-DeKDKD-D"D-D~" 
-.. .. - Donor 
Time aTter transplantation 
Figure 2 Contemporaneous host-versus-gralt (HVG) and graft-versus-host (GVH) rcac-
lions 10 the two-way paradigm of transplantation immun"ology. Arter the initial interaction. 
the evolution or tolerance of each leukocvte population to the other is seen as a low-grade 
,umulatorv ,tate that may wax and wane rather than a deletional one. (Uy permIssion 01 
fmmunolof.!v Todav.) 
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who previously were thought to have complete donor cell chimerism (Figure I D) 
[53,54]. 
B. Experimental Evidence 
The microchimerism following organ transplantation has been studied extensively 
in a variety of rat and mouse allograft models [55-69]. Although limited tissue or 
blood sampling of patients bearing organ allografts does not always reveal the 
microchimerism [44,70-73], the experimental studies have shown that the failure to 
find donor leukocytes in a long surviving organ allograft recipient simply reflects an 
inadequate search [59,66,67]. The cumulative evidence from the experimental stud-
ies has all but eliminated the alternative possibility that the microchimerism may be 
an effect rather than the cause of organ allograft acceptance [74,75]. The answer to 
this "chicken or egg first?" question [76] was the same as in historical investigations 
of florid chimerism [77-80]. 
Also in accord with classical studies, the quantity and lineage composition 
of the donor leukocytes contained within the transplanted rodent organs strongly 
influenced their survival in the recipient and determined whether the chimerism 
that they produced was associated with lethal GVHD or graft acceptance [66]. 
Nonparenchymal cells of the liver (the most tolerogenic whole organ) resembled 
bone marrow cell suspensions in that both contained higher numbers of immature 
leukocytes and cells of myeloid origin than the lymphocyte-rich and GVHD-prone 
intestinal allograft or allogenic lymph node or spleen cell suspensions [66]. 
Thus. the difference between the chimerism produced by classical bone mar-
row transplantation and that produced by the migratory leukocytes from whole 
organs has appeared to be largely semantic. dose-dependent. and influenced by the 
lineage profile of the "passenger leukocytes" contained in the organ allograft. In 
line with this conclusion. the changes following transplantation to noncytoablated 
rodent recipients of the hind limb with its rich bone marrow content are much the 
same as those after engraftment of visceral organs [81). 
c. The Role of Immunosuppression 
A protective umbrella of immunosuppression is usually needed for the survival of 
the minority population [66] (Figures IC and 2). However. this may be only a 
temporary requirement after out bred canine liver [82] and kidney transplantation 
[83-861 and in rodent models too numerous to cite of liver. heart. lung, and kidney 
transplantation. Moreover. the permanent acceptance of liver allografts is possible 
with no treatment at all in a significant percentage of outbred pigs [87-90) and 
several rat strain [91,92) and virtually all mouse strain combinations [59). Mouse 
heart [59,93] and kidney allografts [94] are also accepted without the need for 
immunosuppression in a much more limited number of MHC disparate circum-
stances. In all of these animal models. the allograft passes through an acute self-
resolving rcjection on the way' te tolerance. The tolerance induced by the organ 
variably extends to other donor tissues and organs [59.66.91 -95] despite the fact 
that antidonor reactivity determined with in vitro tcsting is almost invariably re-
(ained (split tolerance) [66.96-981 or can be restored by (he addition of the appro-
I , 
l 
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priate cytokines to the cultures. Species-specific tolerogenic effects of the liver also 
have been demonstrated after hamster ..... rat xenotransplantation [99]. 
Organ tolerogenicity also occurs in humans. especially after liver transplanta-
tion (44], but at a slower and unpredictable pace. By October 1995, 12 (28070) of our 
42 longest surviving liver recipients (13-112 to 26 years post operative) had stopped 
their immunosuppressive drugs. The nearly equal cumulative duration of the 12 
patients off immunosuppression (shaded) and under treatment (shown in black) is 
evident in Figure 3. At present. however, it is not possible to determine by immuno-
logical testing which patients can be weaned from therapy. In a more recent prospec-
tive trial [100] that now includes 95 patients [101]. weaning was started > 5 years 
post transplantation. In the first 80 cases. in 30% of the recipients. including some 
with proven microchimerism. rejection developed. necessitating resumption of 
maintenance immunosuppression (Figure 4). Thus. although many of the long sur-
viving MHC mismatched cadaveric human liver recipients no longer need immuno-
suppression. some probably can never aspire to be drug-free. Even in such patients. 
however. the disseminated donor-derived leukocytes (and their companion organ) 
apparently can be maintained for a lifetime under continuous immunosuppression. 
The same principles apply with less tolerogenic organs. Discontinuance of 
immunosuppression is thought to be more dangerous in nonhepatic recipients. Nev-
ertheless. 5 of our IO longest surviving living related kidney recipients (all treated 
before March 1964 [102)) have been off all immunosuppression for 3 to 30 years 
42 
64 
73 
Vl 92 
<lJ 
.0 105 E 
::l 125 c: 
2 144 
.92 
co 150 
n. 
169 
189 
191 
202 
0 
, 
/,',-'// <///'//'-":'/-'>' 
10 
Years post-transplant 
20 
_ImmunosuppressIOn ;:J No Immunosuppression 
30 
Figure 3 Time on and orf of immunosuppression (gray) of I:! long surViving liver reCipients 
who were receiving no drug treatment In October 1995. Patients 150 and 169 stopped medica-
tIOn less than 2 years posttransplantauon because of noncompliance. The olhers were weaned 
because of compllcauons 01 chromc Immunosuppression. fhese I:! pallents represent 28070 01 
the 42 III our tOlal experience who have conllnuouslv borne hepatlc allografts lor 15 to 25·5i6 
\ ears. 
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Weaning interrupted* 
n = 12 (15%) 
Rejection 
n = 24 (30%) 
• unreliable followup = 4 
physIcian panic = 3 
biliary Iract disorder = 2 
PBe recurrence = 1 
renal failure = 1 
SlealohepallliS = 1 
Off drugs 29 ± 20 months 
n = 22 (27.5%) 
Mean weaning duration 
~~!~~~ 1.5 Years 
Ongoing weaning 
n = 22 (27.5%) 
Mean duration 25 ± 12 Months 
Stanl et al. 
Figure 4 Summary of the first 80 liver recipients in a prospective weaning trial by the 
University of Pittsburgh Medical Center (n = 80). Note that more than half of the patients 
are completely off drugs or are on an uninterrupted schedule of drug reduction. The rate of 
weaning has been slowed from that used originally because of a 30070 incidence of rejection 
(see text). There have been no patient or graft losses. Weaning was interrupted if noncompli-
ance was detected or in the presence of intrinsic liver disease. including the reemergence of 
autoimmune disorders. 
(Table 2). Patients 3 and 4, whose mixed lymphocyte reaction (MLR) test results 
showed a profoundly depressed reaction to donor and third-party targets before 
drug withdrawal [451, had prompt restoration of response to both in the drug-free 
state but with no evidence of rejection. 
D. The Stem Cell Question 
The persistence of multilineage donor cells in human organ recipient tissues for up 
to 30 years after transplantation has been construed as prima facie evidence of the 
presence of hematopoietic stem and precursor cells among the donor leukocytes that 
Table 2 Discontinuance of Immunosuppression in Long·Term Living Related Kidney 
Recipients· 
Haplotype I ndicatlon for 
Patient Years post Tx mismatch • h weaning Years 01 r drugs 
I (KP) 33 0 Nc 30 
:! (SM)' 32 Comp 15 
3 (IN) 32 0 Nc 29 
4 (JW)' 32 2 Comp 3-112 
5 (OS)' 33 Comp 3 
'These are 5 of the 16 longest tunCtlonlng allogralls In the world. 
'Compo ,omplicallons: skin ,ancer. warts. Inlccllon. hypertensIOn. obesHv. orthopedIC problems; 
:>Ic. noncompliant. 
These were children Jl Ihe lime ot Iransplantallon. 
I 
t 
! I, 
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migrate from the organ allografts (\03,104). This belied the widely held belief that 
hematolymphopoietic stem cells in adult mammalian life require a bone marrow 
microenvironment. In interdiction of this axiom, it has been shown that all hemato-
lymphopoietic lineages in supralethally irradiated mice (9.5 Gy) can be reconstituted 
as efficiently as with bone marrow by the infusion of stem cells isolated from 
syngeneic adult mouse livers (105-107). 
The contention that stem cells are present in the adult liver and in other organs 
(but in smaller numbers) has been upheld by direct experimentation. Irradiated rats 
can be reconstituted with the expedient of orthotopic liver transplantation just as 
reliably as with bone marrow (108). Importantly, heterotopic heart transplantation 
had a therapeutic effect similar to that of 0.5 x let infused donor bone marrow 
cells or a large blood transfusion, allowing permanent hematopoietic reconstitution 
of occasional cardiac recipients and prolongation of survival of almost all other 
[108]. This occasional rescue is increased to nearly 100% by the post-cardiac trans-
plantation administration of Iisofylline (Murase et a1.. manuscript in preparation). 
This phosphatidic acid inhibitor facilitates bone marrow engraftment by suppress-
ing hematopoiesis-inhibiting cytokines (tumor necrosis factor a (TNF-a). TGF-I3. 
macrophage inhibitory protein I-a. platelet factor 4. etc.) released in response to 
activation stimuli (interleukin I [IL-I]. IL-8, lipopolysaccharide [LPS). platelet acti-
vating factor (P AF], cellular transformation) that are typical in the posttransplant 
period while not altering levels or activities of the myeloid progenitor cell promoting 
cytokines granulocyte colony-stimulating factor (G-CSF) and granulocyte macro-
phage colony-stimulating factor (GM-CSF) (109). 
V. UNIFICATION OF THE ONE· AND TWO-WAY 
PARADIGMS 
In the context of the two-way paradigm, the suppressor and veto cells, changes in 
cytokine profile, and enhancing antibodies seen in allograft recipients are tolerance 
effector mechanisms. secondary to the seminal event of donor/recipient leukocyte 
engagement (Figure Ie and D). With this new mind-set. the vast reservoir of infor-
mation obtained with reductionist in vitro and in vivo methods in efforts to eluci-
date the deeper meaning of tolerance can be brought to bear on problems of trans-
plantation. 
Many of the purest of such experiments have been one-way paradigmatic. 
showing the effects of exogenous or transgenic antigen or T lymphocytes and other 
immune cell sUbpopulations. The intellectual adjustment required for application 
of such data to transplantation is envisioning the alterations in two immunocyte 
populations. each of which can modulate the other. In addition to a mutual antigen 
stimulus. the two-way paradigm implies an active self-protective effect (GVH or 
HVG) of the coexisting arms that is particularly important if one cell population is 
outnumbered and if there is severe MHC disparity. This "defensive" mechamsm of 
engraftment facilitation was first suggested by Malhe et al. I I \0) and Vriesendorp 
[I I 11 and discussed subsequentlv hy Gale and Reisner (1121 and Plotnicky and 
Touraine (113) but only in wnncl.:tion wllh hemalolymphopoietic rewnstititution 
alter reclpient cytoablation. 
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A. Leukocyte Subsets 
"T cell tolerance" has been the term used for successful experimental manipulations 
in a spectrum of highly controlled conditions. There has been much evidence, how-
ever, that the T lymphocytes are directed by specialized immune regulatory leuko-
cytes of T cell or unknown lineage (i.e., veto [1141 and suppressor [1151 cells). 
Burlingham et al. [1161 have isolated a circulating donor leukocyte of unknown 
lineage in a tolerant human kidney recipient with such powerful veto function that 
a single cell can neutralize the in vitro activity of 10,000 recipient cytotoxic T 
lymphocytes (CTLs). 
The probability that professional antigen presenting cells (APes) ultimately 
govern transplantation tolerance (discussed by Steinman, lnaba, and Austyn [117]) 
was raised by the invariably prominent presence of dendritic cells (Des) in chimeric 
human [42,441 and animal organ recipients [56,591. Using culture techniques devel-
oped by lnaba et al. [1181, donor-derived De precursors have been propagated 
from disseminated locations in mouse recipients of spontaneously accepted liver 
allografts, admixed with recipient Des, presumably undergoing the same changes 
[104,119,1201 (Figure 5). These immature Des, which are phagocytic [1211 and 
deficient in surface costimulatory molecule expression (B7 family) [1221, have been 
shown to induce T cell hyporesponsiveness in vitro and to prolong organ allograft 
survival [1231. 
B. Multimechanistic Hypotheses 
Such clues are intriguing, but it is unlikely that allograft acceptance can be fully 
comprehended from the results of studies of individual leukocyte phenotypes [471. 
Freemartin cattle 
(1945) 
ParabiosIs 
(1960) 
.ry --.-
... 
i 
Billingham/Brent 
Medawar 
(1953\ . 
Slavln/Strooer 1 19Ti1 
Iidstao/Sacns 11984\ 
Thomas 119871 
Organ Tx 
( 1992) 
Figure 5 Conllnuum of chimerism from observallons of Ray Owen In frccmarlln cattle to 
the discoverv In 1992 of microchimensm In organ rCClpICnlS. 
·_---, ------------
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Instead. the events leading to this state suggest learning (cognitive) and intelligence 
functions of the immune system that are properties of the networks postulated to 
explain tolerance to nonliving antigens by Jerne [21]. Coutinho [22]. Cohen [23]. 
and Waldmann et a1. [1241. Network activity under the circumstances of transplan-
tation presumably would be multi mechanistically influenced by cytokines. immuno-
regulatory cells. antibodies. and other factors. 
Such multimechanistic hypotheses have been advanced in the past in the con-
text of the one-way paradigm [125-1281, at first with little consideration of the far 
reaching implications of the two-signal theory articulated by Bretscher and Cohn 
[129] and extended by Jenkins et al. [1301 and Schwartz [1311. After the concept of 
nonlethal clonal silencing was elaborated and experimentally supported by Nossal 
[27,1321, effector immunocytes could be envisioned as surviving in a quiescent. 
anergic, or activated state, or alternatively proceeding to apoptosis [133-1351. Con-
sidering the shifting details of signalling and response involved in the merger of two 
interactive and genetically controlled immune systems of the two-way paradigm. 
~ , computer modeling based on known and experimentally verifiable events may be 
l .' required to comprehend the total process. , ..
. -
1 
C. Is Acquired Tolerance Thymic? 
The role of the thymic versus peripheral mechanisms [136] in graft acceptance 
under clinical circumstances has been controversial. The prompt appearance of 
donor-derived leukocytes in the recipient thymus after organ transplantation was of 
particular interest because of the strikingly tolerogenic effect in rodents of intra-
thymic inoculation of donor leukocytes [137,1381. However, thymectomy in adult 
rates does not influence either the chimerism or spontaneous tolerance induced 
by liver transplantation (63]. Dejbakhsh-Jones et al. [139] have shown that after 
thymectomy and lethal irradiation in adult mice reconstituted with purified hemato-
lymphopoietic stem cells. ap T cells developed no differently than in control animals 
except for a reduced proportion in the spleen. 
Between 1962 and 1965. 32 patients. including 24 who were part of a con-
trolled randomized trial. underwent transthoracic thymectomy from 8 to 112 days 
(average 22) before renal transplantation from living related or unrelated donors. 
After 3-112 to 7 years, no clinical differences were apparent between the thymecto-
mized and control recipients. although there was a trend to better histopathological 
findings in the thymectomy group [140J. In 1992. comprehensive in vitro immuno-
logical studies of many of the remaining recipients and their donors did not reveal 
any distinguishing features of one cohon versus the other (Gene Shearer and Adri-
ana Zeevi. unpublished observations). After 25 to 30 years. the thymectOmized 
patiems had no clinical advamage or disadvantage. 
O. The Parking Models 
Although parking experiments have been put to good use in transplantation research 
[141.1421. the altered (nonreactive) leukocytes that -repopulate an organ during resi-
dency in the imermediary allogenel\; host disqualifv the graft's relranspiamallOn for 
qudy of complex tolerance mechantsms. In addition. the leukocyte replacement 
Juring the parking penod is nor complete. Evcn at I year of residcnce 10 a IOlcrant 
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recipient, IOOJo of the nonparenchymal cells (NPCs) remain donor, a proportion 
that is essentially fixed from day 100 onward [56]. Not surprisingly, the results after 
the second-stage procedure have been uninterpretable [69,143]. 
In simpler experiments involving only the depletion of organ leukocytes by 
donor irradiation, both the tolerogenicity and antigenicity of heart [135] and liver 
allografts [68] are abrogated or weakened. Tolerogenicity can be restored by an 
infusion of donor strain splenocytes 24 hours before the organ is removed for 
transplantation [144]. The necessary presence of donor leukocytes for tolerogenicity 
also has been unequivocally shown with pancreatic islet transplantation into the 
thymus [137] and in several other related models. 
VI. WHAT IS HUMAN TRANSPLANTATION 
TOLERANCE? 
Permanent drug-free graft acceptance after a course of immunosuppression usually 
is termed "operational tolerance" to distinguish it from the ostensibly pristine neo-
natal tolerance of Billingham, Brent, and Medawar [2,3]. However, Streilein has 
demonstrated not only how heterogeneous the outcome in the acquired neonatal 
tolerance model actually is, but how uncommon it is to achieve a state resembling 
complete donor-specific clonal deletion [145]. Alard et al. [146] have recently shown 
in these chimeric animals that the ability of donor-derived leukocytes to proliferate 
in response to a skin graft challenge was a more critical determinant of tolerance 
outcome than the baseline level of chimerism. This was only the latest evidence that 
transplantation tolerance is an active nondeletional process. 
Is the ability of a human allograft recipient to discontinue immunosuppression 
successfully long after either organ or bone marrow transplantation fundamentally 
different from the gold standard tolerance that is so easy to produce with inbred 
rodent models? We do not think so. When we determined donor-leukocyte chime-
rism to be present up to 30 years post transplantation in our organ recipients. we 
realized that all examples of allograft "acceptance," whether immunosuppression-
dependent or not, were variations on the theme originally described by Billingham, 
Brent, and Medawar [2,3]. 
With this finding, it was possible to define both success and failure after 
transplantation in a different way than before. Success "(whether described as) 
tolerance or graft acceptance (meant) that a characteristic lymphoid and dendritic 
cell chimerism had been introduced which may be stable either without further 
treatment, or only when continued immunosuppression is provided" (42). Failure 
connoted a state in which "an unstable graft and its migrated cells may either be 
rejected or cause GVHO" (421. It required no imagination to see the uninterrupted 
thread of chimerism from the observations by Owen (1471 of natural tolerance in 
freemartin cattle to the donor-derived leukocytes found nearly a half century later 
in human and animal recipients of organ allografts. Between these brackets lay the 
rodent neonatal [2.3). cytoablation-dependent [7.81. parabiosis-induced [148). and 
more complicated "mixed chimerism" tolerance models [149-1511 (Figure 5). 
One 01 the lessons emphasized in our first [42) and all subsequent reports of 
organ transplantation-associated chimerISm was that the rapidly evolving drug-free 
,. 
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donor-specific tolerance induced with donor leukocytes in a few days in rodent 
models could not be extrapolated to unrealistic clinical expectations [76,103]. In 
clinical practice, the duration of mutual exposure of the two cell populations neces-
sary permanently to prevent one of the response arms from destroying the other has 
been widely variable, as was illustrated by the liver transplantation weaning trials. 
Moreover, there has been no way, except by trial and error, to determine the amount 
of immunosuppression required during this period. There has not been evidence 
that increasing maintenance drug dosage above the requisite threshold level can 
accelerate the events leading to tolerance; it is likely that excessive therapy may 
prevent achievement of this objective. 
Thus, immunosuppressive agents, which have diverse sites of action [152], do 
not cause tolerance, but rather permit it with variable success by allowing an alterna-
tive normal function of the immune system to be expressed. Chimerism and the 
derivative state of tolerance are almost contemporaneous in numerous rodent mod-
els of liver transplantation (Figure 6). In contrast, the cause (chimerism) and the 
effect (tolerance) are separated by months or years when liver transplantation is 
performed in out bred animals and humans (Figure 6), no matter what the means of 
immunosuppression. In many cases, the desired drug-free end point may never be 
reached. Chimerism (and its companion allograft) can nevertheless be maintained 
for the lifetime of such patients under continuous immunosuppression. 
The folly of using results obtained with rodent models to guide clinical treat-
ment decisions is self-evident. It also is obvious that neither the presence nor the 
quantity of donor leukocyte chimerism can be used per se in planning drug weaning 
protocols for patients. 
Mouse 
Rat 
Plg* 
Dog* 
Human* ? 
Week Month Year Decade 
ONo ImmunosuppressIon .'mmunosuppresslon n"eoeo 
* Oultlreo 
? 
Figure 6 Time between cause (chimerISm I and effect Cdunor-specific tolerance) alter liver 
;Jllotr:msplantallon in different species. Note that Immunosuppression IS nOI unlversallv re-
yUlred In three of the five species shown. (By permiSSion ol/mmunoDo~y rEFda~·Kl 
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VII. THE GENETIC CONTROL OF TOLERANCE 
It would be equally absurd to believe that the events after transplantation. including 
the development of tolerance to alloantigens, are not under genetic control. This 
genetic framework has been too well worked out during the last 40 years to warrant 
extensive citation. However, most of the evidence of a precision effect of MHC on 
the outcome of organ transplantation in large mammals has been obtained under 
conditions of a perfect or near-perfect donor-recipient compatibility with surpris-
ingly little fall-off in survival expectations of human organ recipients at various 
lesser levels of mismatching, no matter how extreme the incompatibility [153-157). 
With bone marrow transplantation. an unambiguous demonstration of the MHC 
effect has depended on simulation of the immunologically defenseless ("one-way") 
neonatal tolerance conditions of Billingham. Brent, and Medawar [2.3) with recipi-
ent cytoablation [33-37.157.158] or on breeding (e.g., the Fl hybrid preparations). 
Under all other circumstances. the results after transplantation. all the way from 
humans to mouse [59] and rat models [65.159], have not been congruent with the 
predications from genetic analyses. 
The two-way paradigm explains why. For all practical purposes, the one con-
stant factor for induction of lasting transplantation tolerance has been chimerism, 
the effects of which far exceed in strength and complexity the mere presence of 
nonliving donor antigen. Consequently, successful organ transplantation requires 
conditions that allow assimilation 0 f the fragment of the donor immunological 
system introduced with the allograft into the preexisting recipient network, and vice 
versa. The subsequent reciprocal modulation of the large and the small immunologi-
cal apparatus is determined within feasibility boundaries that are genetically pro-
scribed for each. 
In his recent review of two books on the history of immunology (160,161], 
Rosen remarked. "Having solved the problem of the molecular basis of specificity, 
immunology reached the end of its history" (\621. However. all properties of the 
immune system cannot be explained with the concept of a genetically "hard-wired 
self." Tauber has suggested that such a bias is derived from a Western individualistic 
philosophy of how humans relate to the world (28). In our view, MHC did not 
evolve to permit immunological segregation but rather to meet the need of popula-
tions, not individuals, for immunological flexibility. In this context. the genetic 
issue is not self versus nonself so much as the ability of the population to adapt to 
change and the survival need for such maneuverability. Allograft rejection was, of 
course. an unforeseen by-product. and transplantation of surgically revascularized 
allografts was, in essence, the production and then control of an organ-specific 
autoimmune disease. Thus. contrary to Burnet's concern (29). there were no biologi-
cal rules that prohibited chimerism or successful organ transplantation. 
VIII. THERAPEUTIC IMPLICATIONS 
The two-way paradigm all6ws predictions about what can (and cannot) be accom-
plished with tolerance inducing strategies. all of which are auempts to alter the 
donor/recipient leukocyte interaction. It has been established that when both immu-
nocyte populatlons are competent. and when lmmunosuppression IS delivered to the 
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two arms equally, the microchimerism produced by organ transplantation can be 
greatly augmented by the coadministration of 3-6 x 108/kg unmodified donor 
bone marrow cells without a significant risk of GVHD [163]. The presence of donor 
deoxyribonucleic acid (DNA) in the myeloid and erythroid colonies generated from 
recipients' peripheral blood mononuclear cells (PBMCs) by using standard clonal 
hematopoietic progenitor cell assays provided unequivocal evidence of engraftment 
[164]. These findings have been confirmed and extended by Garcia Morales et al. 
[165], using innovative clonal hematopoietic progenitor cells assays. 
Despite the increase of persistent chimerism to levels many times higher tha.n 
that in control patients neither the timing, severity, nor frequency of acute rejection 
has been different than in non-marrow-augmented control patients [163-165] (Fig-
ure 7). It had not been anticipated that these endpoints would be altered. The 
hypotheses being tested are, first, that the threat of chronic organ rejection will be 
reduced. and. second, that the frequency of ultimate drug independence can be 
increased by achieving a higher persistent level of chimerism. An efficacy evaluation 
is expected to take 5 to 10 years, roughly the same time frame (Figure 6) delineated 
by three decades of clinical experience with MHC-incompatible liver and bone 
marrow transplantation [103]. 
The administration of colony stimulating hematolymphopoietic growth fac-
tors (e.g., GM-CSF) or drugs like lisofylline (discussed earlier) is predicted to be 
without significant risk of GVHD if such chimerism augmenting treatment is im-
posed on both cell populations equally. In contrast. procedures that alter only one 
of the interacting arms must be approached with caution, as exemplified by the 
historical experience with GVHD after cytoablation and bone marrow transplanta-
tion. When the converse tactic of leukocyte- or T cell-specific depletion of intestinal 
100l 
...... sJ 
~ 
1 
~ 
a: 
u 
c( 60, 
-0 l ~ en .;: 
41 
.. 01 K~ i iii 
:i i E 
::l ~g . 
U 
......... ---.-_. . .... _ ............... .. 
- 8M-Augmented Group (n:: 150) 
···Control (n=95) 
p=0.533 (Log·rank test) 
." '8 :'1 :0 
Months after transplantation 
Figure 7 Cumulative Incidence of rejectIOn In hone marrow-augmented and -Ilonau!l· 
mented or!!an allograft reCipients. 
498 Stanl et a/. 
allografts was attempted in the 1980s as GVHD prophylaxis, in virtually every bowel 
recipient who survived the transplantation lethal Epstein-Barr virus-associated B 
cell lymphomas developed [52]. 
The highest priority in transplantation today is the clinical development of 
xenografting techniques. Although the interspecies activation of complement may 
be preventable with the creation of transgenic or otherwise altered animal donors, it 
is naive to believe that the success of xenotransplantation procedures will not in-
volve the manipulation and control of the same bidirectional immune reactions as 
with allografts and the ultimate establishment of stable chimerism. 
IX. CONCLUSION 
The unwarranted assumption that stem cell-driven hematolymphopoietic chimerism 
was irrelevant to successful whole organ transplantation as currently practiced led 
to alternative inadequate explanations of organ allograft acceptance. clouded the 
meaning of successful bone marrow transplantation, and precluded for more than 
three decades the development of a cardinal principle of transplantation. Recogni-
tion of this error and incorporation of the chimerism factor into a two-way para-
digm have allowed previous enigmas of organ as well as bone marrow engraftment 
to be explained and should allow the vast foundation of basic immunology to be 
more meaningfully exploited in transplantation. In turn, experimental examination 
of the mechanisms of the two-way immune interaction implicit in this concept may 
further elucidate the meaning of selflnonself discrimination. 
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